Healthcare Industry News: Side Branch Stent
News Release - October 17, 2006
Professor Patrick W. Serruys, Thoraxcenter, Rotterdam, Joins Tryton Medical's First-in-Man StudyThoraxcenter, Rotterdam, Uses Tryton Medical's Side-Branch Stent(TM), Treats Coronary Bifurcation Lesions, Eliminates Need for Provisional Stenting
NEWTON, Mass.--(HSMN NewsFeed)--Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that the Thoraxcenter, Rotterdam joined Tryton Medical's First-in-Man Study and have successfully used Tryton's Side-Branch Stent without in-hospital complications in two patients. "Tryton's Side-Branch Stent eliminates the need for provisional Side Branch Stenting by preserving the side branch without compromising access to the main vessel," said Professor Patrick Serruys, Head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. "This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist," said Professor Serruys.
"Unlike other stents and techniques used to treat bifucration lesions, Tryton's stent is easy to deliver as it uses standard equipment and techniques compatible with 5 and 6 French guiding catheters," said Dr. George Sianos, Senior Interventionalist, Thoraxcenter, Erasmus Medical Center. "This device has greatly facilitated the treatment of these patients. Interventional cardiologists who use Tryton's stent will no longer have to worry about the bifurcation as they will know the side-branch will stay open and the interventionalist is then free to focus on the treatment of the main vessel using their preferred choice of standard equipment," said Dr. Sianos.
Tryton's First-In-Man Study is a multi-center clinical trial evaluating the safety of Tryton's Side-Branch Stent in the treatment of coronary bifurcation lesions. The Study is also being performed the HELIOS Heart Center/Siegburg, Germany under the direction of Prof. Eberhard Grube, Principal Investigator. The Institut Cardiovasulaire Paris Sud, France (Prof. Marie-Claude Morice, Principal Investigator) is scheduled to start enrollment as well. During this study, Tryton's stents have been used in conjunction with a standard workhorse stent to treat a wide spectrum of bifurcation lesions with superior angiographic results and without major adverse cardiac events. 540,000 bifurcation coronary lesions are sub-optimally treated every year as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent-- leaving the side branch vulnerable to thrombosis and restenosis.
To see pictures of pre and post-angiographic results that show the Tryton Side-Branch Stent benefits, visit www.TrytonMedical.com and click on "Save the Side Branch".
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution is commercially available for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent-- leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
Tryton Medical's Side-Branch Stent(TM) has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions while eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact or visit www.TrytonMedical.com
Source: Tryton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.